Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Vital Signs and ECOG Screening Day -7 to 0 SirTac NCT02936388 - Vital Signs and ECOG Screening Day -7 to 0

- 20/11/2017 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: vital signs, quality of life

Study part: Vital Signs and ECOG Screening Day -7 to 0. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Vital Signs prior to Infusion; Liver Events; Investigational Product (Liver); Pharmacokinetics (Liver); Alcohol Intake; Medical Conditions (Liver)

- 02/04/2020 - 1 Formulaire, 9 Groupes Item, 44 Eléments de données, 1 Langue

Groupes Item: Vital Signs - Prior to Infusion, Liver Events, Investigational Product (Liver), Pharmacokinetics (Liver), Alcohol intake, Medical Conditions (Liver), Drug related liver disease conditions, Other Liver disease conditions, Other medical conditions

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer - Vital Signs

- 29/05/2018 - 1 Formulaire, 1 Groupe Item, 5 Eléments de données, 1 Langue

Groupe Item: Vital Signs

https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Completion of Visit Assessments (Follow- Up); Date of Visit/ Assessment, Vital signs, Candidiasis Examination, Electronically transferred lab data, Liver Events Assessment (Early Withdrawal)

- 23/11/2018 - 1 Formulaire, 7 Groupes Item, 17 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment - Follow- Up, Completion of Visit Assessments, Date of Visit/ Assessment - Early Withdrawal, Vital signs, Candidiasis Examination , Electronically transferred lab data , Liver Events Assessment

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Vital signs, Candidiasis Examination, Device Use Assessment, Subject Withdrawal Status, Electronically transferred lab data, Liver Events Assessment - Visit 4

- 23/11/2018 - 1 Formulaire, 7 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment, Vital signs, Candidiasis Examination , Device Use Assessment , Subject Withdrawal Status , Electronically transferred lab data , Liver Events Assessment

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Vital signs, Candidiasis Examination, Inhaler Ease Of Use Assessment,Device Use Assessment, Subject Withdrawal Status, Electronically transferred lab data, Liver Events Assessment - Visit 5

- 23/11/2018 - 1 Formulaire, 8 Groupes Item, 21 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment, Vital signs, Candidiasis Examination , Inhaler Ease Of Use Assessment, Device Use Assessment , Subject Withdrawal Status , Electronically transferred lab data , Liver Events Assessment

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Unscheduled Assessments Performed, Vital signs, Candidiasis Examination, Electronically transferred lab data, Liver Events Assessment (Unscheduled); Date of Visit/ Assessment, Status of Treatment Blind, Pregnancy Information, Pharmacogenetic (PGx) Research Withdrawal of Consent, Study Conclusion, Investigator Signature (End of Study)

- 23/11/2018 - 1 Formulaire, 12 Groupes Item, 33 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment - Unscheduled, Unscheduled Assessments Performed, Vital signs, Candidiasis Examination , Electronically transferred lab data , Liver Events Assessment , Date of Visit/ Assessment - End of Study, Status of Treatment Blind, Pregnancy Information, Pharmacogenetic (PGx) Research Withdrawal of Consent, Study Conclusion, Investigator Siganture

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 4; 6; 9 - Electronically Transferred Lab Data; ESR; PK Blood Sample; Biomarker Samples; Transcriptomic Research Sample Collection Details; Liver Events

- 23/03/2020 - 1 Formulaire, 6 Groupes Item, 27 Eléments de données, 1 Langue

Groupes Item: Electronically Transferred Lab Data , ESR, PK Blood Sample - Point in Time Collection, Biomarker Samples, Transcriptomic Research Sample Collection Details , Liver Event Assessment

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Unscheduled - Electronically Transferred Lab Data; ESR; Neurological Examination; Vital Signs; Liver Event Assessment

- 24/03/2020 - 1 Formulaire, 5 Groupes Item, 20 Eléments de données, 1 Langue

Groupes Item: Electronically Transferred Lab Data , ESR, Neurological Examination , Vital Signs , Liver Event Assessment

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination, PK Sample, Subject Withdrawal Status, Electronically transferred lab data, Liver Events Assessment- Visit 6

- 23/11/2018 - 1 Formulaire, 10 Groupes Item, 24 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination , PK Sample- Pre Dose, PK Sample - 15 Minutes Post- Dose, PK Sample PK Sample - 1.5 Hours Post- Dose , Subject Withdrawal Status , Electronically transferred lab data , Liver Events Assessment

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Visit Assessments Complete (Visit 2) and Run-In-Failure, Randomisation Criteria, ICS/ LABA Concomitant Medications, Randomisation Number, Investigational Product, Vital Signs, Electronically Transferred Lab Data, Device Use Assessment, Subject Withdrawal Status and Liver Events Assessment(Visit 3)

- 21/11/2018 - 1 Formulaire, 18 Groupes Item, 47 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment , Completion of Visit Assessments, Run- In Failure, Investigator Siganture , Date of Visit/ Assessment , Randomisation Criteria, Run- In Failure , Investigator Siganture , ICS/ LABA Concomitant Medications, Randomisation Number, Investigatinal Product, Vital Signs, Candidiasis Examination, Electronically transferred lab data, Device Use Assessment, Subject Withdrawal Status, Electronically transferred lab data , Liver Events Assessment

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Vsit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination, Electronically transferred lab data, Liver Events Assessment , PK Sample- Pre Dose, PK Sample, Subject Withdrawal Status - Visit 7

- 23/11/2018 - 1 Formulaire, 10 Groupes Item, 27 Eléments de données, 1 Langue

Groupes Item: Date of Visit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination , Electronically transferred lab data , Liver Events Assessment , PK Sample- Pre Dose, PK Sample - 15 Minutes Post- Dose, PK Sample - 1.5 Hours Post- Dose , Subject Withdrawal Status

Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Mots-clés

Table des matières

Modèles de données sélectionnés